Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axil Brands, Inc.AXIL · Entity 7219 | Director | January 15, 2026 | March 04, 2026 |
| GT Biopharma, Inc.GTBP · Entity 7878 | CFO & Secretary | August 11, 2023 | August 15, 2023 |
| Toughbuilt Industries, IncTBLT · Entity 88471 | Director · CFO | November 14, 2018 | February 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axil Brands, Inc.
Report date January 15, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,001 |
Reported balance
After 2026-01-15 transaction · row 1
1 source rowRow 1 · 2026-01-15 · Grant · Acquired 5,000 · Balance 15,001 F1: Represents shares of restricted stock, which will vest on January 15, 2027 and were granted as non-employee director compensation. |
| Common StockSEC Table I · non-derivative | IndirectBy Anarjay Concepts Inc. | 10,000 |
Reported balance
Holding disclosure · report date 2026-01-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,000 F2: Mr. Ohri is the principal of Anarjay Concepts Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of restricted stock, which will vest on January 15, 2027 and were granted as non-employee director compensation.
F2: Mr. Ohri is the principal of Anarjay Concepts Inc.
GT Biopharma, Inc.
Report date August 11, 2023 · Filed August 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-08-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-08-11 · Grant · Acquired 200,000 · Balance 200,000 Row 2 · 2023-08-11 · Other · Disposed 200,000 · Balance 0 F1: The reporting person transferred the shares without consideration to Anarjay Concepts, Inc., a corporation wholly-owned by the reporting person. |
| Common StockSEC Table I · non-derivative | IndirectBy Anarjay Concepts, Inc. | 300,000 |
Reported balance
After 2023-08-11 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-08-11 · Other · Acquired 200,000 · Balance 300,000 F1: The reporting person transferred the shares without consideration to Anarjay Concepts, Inc., a corporation wholly-owned by the reporting person. |
| Common StockSEC Table I · non-derivative | IndirectBy Ohri Family Revocable Trust U/A Dated 02/10/2020 | 50,000 |
Reported balance
Holding disclosure · report date 2023-08-11 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 50,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person transferred the shares without consideration to Anarjay Concepts, Inc., a corporation wholly-owned by the reporting person.
Toughbuilt Industries, Inc
Report date November 14, 2018 · Filed February 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,750 |
Reported balance
Holding disclosure · report date 2018-11-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 88,750 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.90 · Expires 2023-06-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-11-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Vests in four equal annual amounts on the grant date, and the one, two and three year anniversaries of the grant date. |
| Series A WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2023-11-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-11-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed |
| Series B WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2019-11-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-11-14 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in four equal annual amounts on the grant date, and the one, two and three year anniversaries of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2026 Filed Mar 4, 2026 18:11 UTC | Axil Brands, Inc. AXIL · Entity 7219 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-26-000066 · ownership.xml · nonDerivative · entry 1 Ohri Manu · CIK 0001424683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,001 F1 · shares: Represents shares of restricted stock, which will vest on January 15, 2027 and were granted as non-employee director compensation. Read SEC document |
| January 13, 2025 Filed Jan 13, 2025 06:00 UTC | Axil Brands, Inc. AXIL · Entity 7219 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-25-000033 · ownership.xml · nonDerivative · entry 1 Ohri Manu · CIK 0001424683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,001 F1 · shares: Represents shares of restricted stock, which will vest on January 13, 2026 and were granted as non-employee director compensation. Read SEC document |
| February 14, 2024 Filed Feb 20, 2024 16:32 UTC | Axil Brands, Inc. AXIL · Entity 7219 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-003687 · form4.xml · nonDerivative · entry 1 Ohri Manu · CIK 0001424683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,001 F1 · shares: This restricted stock award was granted under the Reviv3 Procare Company 2022 Equity Incentive Plan in a transaction exempt under Rule 16b-3 and vests on February 14, 2025, except as otherwise provided in the award notice. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 23:26 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | OtherCommon Stock | 200,000 | $0.29 | $57,400.00 |
DisclosureSEC source: 0001493152-23-029059 · ownership.xml · nonDerivative · entry 3 Ohri Manu · CIK 0001424683 · CFO & Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · By Anarjay Concepts, Inc. Disclosed balance after: 300,000 F1 · kind: The reporting person transferred the shares without consideration to Anarjay Concepts, Inc., a corporation wholly-owned by the reporting person. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 23:26 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | OtherCommon Stock | 200,000 | $0.29 | $57,400.00 |
DisclosureSEC source: 0001493152-23-029059 · ownership.xml · nonDerivative · entry 2 Ohri Manu · CIK 0001424683 · CFO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The reporting person transferred the shares without consideration to Anarjay Concepts, Inc., a corporation wholly-owned by the reporting person. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 23:26 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantCommon Stock | 200,000 | $0.29 | $57,400.00 |
DisclosureSEC source: 0001493152-23-029059 · ownership.xml · nonDerivative · entry 1 Ohri Manu · CIK 0001424683 · CFO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 21:26 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | PurchaseCommon Stock | 50,000 | $0.50 | $25,000.00 |
DisclosureSEC source: 0001493152-23-011772 · ownership.xml · nonDerivative · entry 1 Ohri Manu · CIK 0001424683 · CFO & Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · By Ohri Family Revocable Trust U/A Dated 02/10/2020 Disclosed balance after: 50,000 Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 11:02 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 500,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001493152-23-003227 · ownership.xml · derivative · entry 1 Ohri Manu · CIK 0001424683 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-01-26 F1 · derivative.exercise_date: 1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is involuntarily terminated by the registrant. Read SEC document |
| July 15, 2022 Filed Jul 20, 2022 01:44 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 200,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001493152-22-019872 · ownership.xml · derivative · entry 4 Ohri Manu · CIK 0001424683 · CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-07-14 F2 · derivative.exercise_date: 66,666 shares on the date of grant, and 66,667 shares on each February 14, 2023 and 2024. Read SEC document |
| July 15, 2022 Filed Jul 20, 2022 01:44 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | OtherCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019872 · ownership.xml · nonDerivative · entry 3 Ohri Manu · CIK 0001424683 · CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · By Anarjay Concepts, Inc. Disclosed balance after: 100,000 F1 · kind: The reporting person transferred the shares without consideration to Anarjay Concepts, Inc., a corporation wholly-owned by the reporting person. Read SEC document |
| July 15, 2022 Filed Jul 20, 2022 01:44 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | OtherCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019872 · ownership.xml · nonDerivative · entry 2 Ohri Manu · CIK 0001424683 · CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reporting person transferred the shares without consideration to Anarjay Concepts, Inc., a corporation wholly-owned by the reporting person. Read SEC document |
| July 15, 2022 Filed Jul 20, 2022 01:44 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019872 · ownership.xml · nonDerivative · entry 1 Ohri Manu · CIK 0001424683 · CFO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.